Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Public ClinicalTrials.gov record NCT04186819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.
Study identification
- NCT ID
- NCT04186819
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 356 participants
Conditions and interventions
Conditions
Interventions
- rhPSMA-7.3 (18F) Injection Drug
- Positron Emission Tomography scan Diagnostic Test
Drug · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2, 2020 (Actual)
- Primary completion
- Jun 21, 2021 (Actual)
- Completion
- Jun 21, 2021 (Actual)
- Last update posted
- Feb 26, 2025
2020 – 2021
United States locations
- U.S. sites
- 29
- U.S. states
- 15
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Tower Urology | Los Angeles | California | 90048 | — |
| University of California Irvine Medical Center (UCIMC) | Orange | California | 92868 | — |
| John Wayne Cancer Institute | Santa Monica | California | 90403 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Northside Hospital | Austell | Georgia | 30342 | — |
| NorthShore University HealthSystem | Evanston | Illinois | 60201 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Richard L Roudebush VA Medical Center | Indianapolis | Indiana | 46278 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Chesapeake Urology Research Associates | Towson | Maryland | 21204 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| University of Michigan, Ann Arbor | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| The Urologic Institute of Northeastern New York - Community | Albany | New York | 12208 | — |
| Queens Hospital Center (QHC) - Queens Cancer Center | Jamaica | New York | 11432 | — |
| Mount Sinai Faculty Practice Associates | New York | New York | 10029 | — |
| Stony Brook University | Stony Brook | New York | 11794 | — |
| Montefiore Hospital | The Bronx | New York | 10461 | — |
| Duke University Medical Center | Durham | North Carolina | 27701 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| MidLantic Urology | Philadelphia | Pennsylvania | 19004 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| MD Anderson Hospital | Houston | Texas | 77054 | — |
| Urology San Antonio | San Antonio | Texas | 78229 | — |
| University of Virginia - Health Science Center | Charlottesville | Virginia | 22908 | — |
| Virginia Oncology Associates PC | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04186819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04186819 live on ClinicalTrials.gov.